Overview

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, efficacy and tolerability of using two regimens of telaprevir (with and without delayed start) with standard treatment compared to standard treatment alone in participants with chronic, genotype 1, hepatitis C.

Phase:

Phase 3

Details

Lead Sponsor:

Tibotec BVBA

Collaborator:

Tibotec Pharmaceutical Limited

Treatments:

Interferon alpha-2
Interferon-alpha
Peginterferon alfa-2a
Ribavirin